Videos

A clinical pharmacy specialist details her experience with the REMS program for administration of belantamab mafodotin in patients with multiple myeloma.

Holowatyj spoke about the molecular differences of early-onset colorectal cancer by race, while maintaining that race is a social construct, leading to a multitude of options for future research.

During an After Hours segment of Medical World News®, Loren Winters, MSN, ANP-BC, OCN, spoke about her passion for health and wellness, expressed through yoga instruction and Ayurvedic health coaching.

The lead author from a study presented at the American Association for Cancer Research Annual Meeting 2021 explained the main findings regarding potential differences in tumor mutation burden by race in patients with early-onset colorectal cancer.

CancerNetwork® spoke with Sanju Sinha of the National Cancer Institute about the resulting data from his research into sex differences associated with using tumor mutational burden to predict response to PD-1 inhibition.

An overview of unmet needs surrounding current treatment patterns for early-stage HR+ breast cancer.

Thoughts regarding how the addition of the Breast Cancer Index to the NCCN guidelines for HR+ breast cancer may likely impact extended adjuvant therapy and patient outcomes.

Dr Reshma L. Mahtani, of Sylvester Comprehensive Cancer Center, describes when and for whom she recommends genomic testing for HR+ breast cancer.

A review of recent updates to genomic testing guidelines by the National Comprehensive Cancer Network and important takeaways that impact treatment decisions for HR+ breast cancer in the extended adjuvant setting.

The rationale for treating early-stage HR+ breast cancer with extended adjuvant therapy and factors that impact treatment selection.

Insights into ongoing unmet needs in the individualized management of HR+ breast cancer and thoughts regarding future directions.

Role of the Breast Cancer Index genomic index in therapeutic decision-making in the extended adjuvant setting in HR+ breast cancer.

A review of NCCN-recommended genomic assays and their impact on the management of HR+ breast cancer.

Best practices for the appropriate and timely use of genomic assays in clinical practice for patients with HR+ breast cancer.

Discussion of predictive and prognostic markers used to guide treatment decision-making in HR+ breast cancer.

The goals of adjuvant therapy versus extended adjuvant therapy for early-stage HR+ breast cancer and current treatment options available for each approach.

Dr Raoul Concepcion leads a multidisciplinary expert panel in a discussion about the challenges of long-term follow-up of prostate cancer in patients with negative bone/CT but positive molecular indicators of recurrence. 

An expert panel discusses the challenges of detecting and managing biochemical recurrence in the context of oligometastatic prostate cancer. 

Dr Munir Ghesani reviews and comments on data regarding the sensitivity of imaging modalities in detecting biochemical recurrence in prostate cancer. 

CancerNetwork® sat down with Hans P.A. Van Dongen, PhD, Shobhan Gaddameedhi, PhD, and Jason McDermott, PhD, to discuss their research into how circadian disruptions may lead to changes in cancer-related genes.

Holowatyj touched on the need to learn more about the biological factors contributing to disparities in early-onset colorectal cancer and the associated burden of the disease.

CancerNetwork® spoke with Francesco Ravera, MD, PhD, during the American Association for Cancer Research Annual Meeting 2021 to discuss how results of a study aimed at determining pathological complete response in patients with locally advanced breast cancer by cell-free DNA may spare certain patients from needing further biopsies.

CancerNetwork® shares its latest investigation into novel practices for rendering surgical management of prostate cancer from experts at Vanderbilt Institute for Surgery and Engineering.

Dr Sagar Lonial, MD, FACP, shares his thoughts on the future of targeted therapies for patients with multiple myeloma.

Sagar Lonial, MD, FACP, provides insight on the potential role of BCMA-targeted therapies for newly diagnosed patients with multiple myeloma.

A leading myeloma expert reviews important data that led to the approval of belantamab mafodotin for heavily pretreated patients with relapsed/refractory multiple myeloma.

Dr Sagar Lonial, MD, FACP, comments on BCMA as a potential therapeutic target for multiple myeloma.

Sagar Lonial, MD, FACP, reviews targeted therapy options, and how they differ from other therapeutic approaches for relapsed/refractory myeloma.

CancerNetwork® spoke with Neelam and Sanju Sinha of the National Cancer Institute about their research into sex differences associated with using tumor mutational burden to predict response to PD-1 inhibition.

A multiple myeloma expert introduces and defines relapsed/refractory myeloma and discusses typical treatment strategies.